Core Insights - INREEDI has completed a new round of financing amounting to several tens of millions of RMB, led by NRL Capital [1] - The funds will accelerate the promotion of its core product, BeaShape radiofrequency therapy device, in domestic and international markets, as well as expand clinical research for new indications and subsequent product pipeline development [1] - INREEDI focuses on low-temperature radiofrequency technology and has successfully launched multiple radiofrequency energy devices, obtaining several Class III medical device registrations [1] Company Overview - INREEDI is a medical device R&D company that emphasizes innovation from foundational technology, aiming to provide radiofrequency treatment solutions that combine "professional-level efficacy" with "consumer-level experience" [1] - The core team consists of industry experts from top global medical companies, with an average of over 15 years of industry experience [1] Product and Market Position - The BeaShape radiofrequency therapy device exemplifies the company's innovative approach and has demonstrated excellent clinical data, comfort, and significant effectiveness, showcasing strong competitive differentiation in the market [2] - NRL Capital believes INREEDI has the potential to become a benchmark enterprise in the wave of domestic innovative consumer medical devices and a significant player in the global radiofrequency medical device sector [2]